Innate Pharma (Nasdaq: IPHA) sets March 26 call on 2025 results

Rhea-AI Filing Summary

Innate Pharma S.A. filed a Form 6-K to share details of an upcoming conference call and webcast for its full year 2025 financial results. The call will take place on Thursday, March 26, 2026 at 2 p.m. CET / 9 a.m. EDT, following the release of results for the year ended December 31, 2025.

Senior leadership, including the Chief Executive Officer, Chief Medical Officer, Chief Operating Officer, Chief Financial Officer and Vice President of Investor Relations, will participate. The event will be accessible via webcast and telephone, with a replay available on the company’s website for 90 days.

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549 FORM 6-K

REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934

Date of report: Thursday March 19, 2026

Commission File Number: 001-39084

Innate Pharma S.A.

(Translation of registrant's name into English)

Innate Pharma S.A.

117 Avenue de Luminy—BP 30191

13009 Marseille, France

+ 33 (0) 4 30 30 30

(Address of principal executive office)

Indicate by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F. Form 20-F [ X ]    Form 40-F [ ]

EXHIBIT INDEX

Exhibit Description

99.1 Press Release dated March 19, 2026

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.

INNATE PHARMA S.A.

Date: March 19, 2026    By:    /s/ JONATHAN DICKINSON     Name:    Jonathan Dickinson

Title:    Chief Executive officer

EXHIBIT 99.1

Innate Pharma announces conference call and webcast for full year 2025 financial results

Marseille, France, March 19, 2026, 7:00 AM CET

Innate Pharma SA (Euronext Paris: IPH; Nasdaq: IPHA) (“Innate” or the “Company”), today announces that the Company will hold a conference call on Thursday, March 26, 2026 at 2 p.m. CET / 9 a.m. EDT, following the release of its financial results for the full year ending December 31, 2025.

Participants during the call will be:

•Jonathan Dickinson, Chief Executive Officer

•Sonia Quaratino, Executive Vice President, Chief Medical Officer

•Yannis Morel, Executive Vice President, Chief Operating Officer

•Stéphanie Cornen, Vice President, Investor Relations, Communication and Commercial Strategy

•Frédéric Lombard, Senior Vice President, Chief Financial Officer

Details for the Virtual Event

The live webcast will be available at the following link:

https://events.q4inc.com/attendee/704730270

Participants may also join via telephone using the following registration link: https://events.q4inc.com/analyst/704730270?pwd=usHLLD39

This information can also be found on the Investors section of the Innate Pharma website, www.innate-pharma.com. A replay of the webcast will be available on the Company website for 90 days following the event.

About Innate Pharma

Innate Pharma S.A. is a global, clinical-stage biotechnology company developing immunotherapies for cancer patients. Leveraging its expertise on antibody-engineering and innovative target identification, Innate Pharma is developing innovative and differentiated next-generation antibody therapeutics.

Innate Pharma is advancing a portfolio of differentiated potential first and/or best-in-class assets, focused on areas of high unmet medical need, including IPH4502, a differentiated Nectin-4 ADC developed in solid tumors, lacutamab, an anti-KIR3DL2 antibody developed in cutaneous T cell lymphomas and peripheral T cell lymphomas, and monalizumab, an anti-NKG2A antibody developed in collaboration with AstraZeneca in non-small cell lung cancer.

Innate Pharma has established collaborations with leading biopharmaceutical companies, including Sanofi and AstraZeneca, as well as renowned academic and research institutions, to advance innovation in immuno-oncology.

Headquartered in Marseille, France with a US office in Rockville, MD, Innate Pharma is listed on Euronext Paris and Nasdaq in the US.

Learn more about Innate Pharma at www.innate-pharma.com and follow us on LinkedIn and X.

Information about Innate Pharma shares

ISIN code FR0010331421

Ticker code Euronext: IPH Nasdaq: IPHA

LEI    9695002Y8420ZB8HJE29

Disclaimer on forward-looking information and risk factors

For a discussion of risks and uncertainties, please refer to the Risk Factors (“Facteurs de Risque") section of the Universal Registration Document filed with the French Financial Markets Authority (“AMF”), which is available on the AMF website http://www.amf-france.org or on Innate Pharma’s website, and public filings and reports filed with the U.S. Securities and Exchange Commission (“SEC”), including the Company’s Annual Report on Form 20-F for the year ended December 31,

2024, and subsequent filings and reports filed with the AMF or SEC, or otherwise made public by the Company. References to the Company’s website and the AMF website are included for information only and the content contained therein, or that can be accessed through them, are not incorporated by reference into, and do not constitute a part of, this press release.

This press release and the information contained herein do not constitute an offer to sell or a solicitation of an offer to buy or subscribe to shares in Innate Pharma in any country.

For additional information, please contact:

Investors & Media Relations

Innate Pharma

Stéphanie Cornen

stephanie.cornen@innate-pharma.fr

Investor Relations

investors@innate-pharma.fr

Media

communication@innate-pharma.fr

FAQ

When will Innate Pharma (IPHA) discuss its full year 2025 financial results?

Innate Pharma will discuss its full year 2025 financial results on a conference call and webcast on Thursday, March 26, 2026 at 2 p.m. CET / 9 a.m. EDT. The event follows the release of results for the year ended December 31, 2025.

How can investors access Innate Pharma’s March 26, 2026 earnings conference call?

Investors can access Innate Pharma’s March 26, 2026 conference call via a live webcast at the provided Q4 Inc. link or by registering for telephone access. A replay of the webcast will be available on the company’s website for 90 days after the event.

Which Innate Pharma executives will participate in the 2025 results conference call?

Participants will include Chief Executive Officer Jonathan Dickinson, Chief Medical Officer Sonia Quaratino, Chief Operating Officer Yannis Morel, Chief Financial Officer Frédéric Lombard, and Vice President Investor Relations, Communication and Commercial Strategy Stéphanie Cornen. This leadership group will discuss Innate Pharma’s full year 2025 financial results with investors and analysts.

What type of company is Innate Pharma (IPHA) and what does it develop?

Innate Pharma is a global, clinical-stage biotechnology company developing immunotherapies for cancer patients. It focuses on next-generation antibody therapeutics, including IPH4502, lacutamab and monalizumab, targeting high unmet medical needs in solid tumors, cutaneous T cell lymphomas, peripheral T cell lymphomas and non-small cell lung cancer.

On which stock exchanges are Innate Pharma shares listed and under what tickers?

Innate Pharma shares are listed on Euronext Paris under ticker IPH and on Nasdaq in the United States under ticker IPHA. The company’s ISIN code is FR0010331421, and it maintains listings in both Europe and the U.S. to reach a broad investor base.

Where can investors find Innate Pharma’s risk factors and regulatory filings?

Investors can find Innate Pharma’s risk factors in its Universal Registration Document on the AMF website and on the company website. They can also review the Annual Report on Form 20-F for the year ended December 31, 2024 and subsequent filings with the U.S. SEC.

Filing Exhibits & Attachments

1 document

Press Releases

• EX-99.1 EX-99.1 13.9 KB